Modelling the effects of adherence to the HIV fusion inhibitor enfuvirtide

被引:15
|
作者
Lou, Jie [1 ]
Smith, Robert J. [2 ,3 ]
机构
[1] Shanghai Univ, Dept Math, Shanghai 200444, Peoples R China
[2] Univ Ottawa, Dept Math, Ottawa, ON K1N 6N5, Canada
[3] Univ Ottawa, Fac Med, Ottawa, ON K1N 6N5, Canada
基金
加拿大自然科学与工程研究理事会;
关键词
Enfuvirtide; Fusion inhibitors; Antiretroviral therapy; Mathematical model; Adherence; IMMUNOLOGICAL MODEL; DRUG-RESISTANCE; INFECTION; DYNAMICS; THERAPY; ENTRY;
D O I
10.1016/j.jtbi.2010.09.039
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Recently, the first drug in a new class of antiretroviral HIV drugs was approved, the fusion inhibitor enfuvirtide. We develop a mathematical model that describes the binding of the virus to T cells. We model the effect of enfuvirtide upon this process using impulsive differential equations. We find equilibria and determine stability in the case of no therapy and then when therapy is taken with perfect adherence. We determine analytical thresholds for the dosage and dosing intervals to ensure the disease-free equilibrium remains stable. We also explore the effects of partial adherence. Our theoretical results suggest that partial adherence may, at times, be worse than no therapy at all, but at other times may in fact as good as perfect adherence. It follows that patients should be counselled on the importance of adherence to this new antiretroviral drug. (C) 2010 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1 / 13
页数:13
相关论文
共 50 条
  • [31] Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus
    Dwyer, John J.
    Wilson, Karen L.
    Davison, Donna K.
    Freel, Stephanie A.
    Seedorff, Jennifer E.
    Wring, Stephen A.
    Tvermoes, Nicolai A.
    Matthews, Thomas J.
    Greenberg, Michael L.
    Delmedico, Mary K.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2007, 104 (31) : 12772 - 12777
  • [32] Potent HIV fusion inhibitors against Enfuvirtide-resistant HIV-1 strains
    He, Yuxian
    Cheng, Jianwei
    Lu, Hong
    Li, Jingjing
    Hu, Jie
    Qi, Zhi
    Liu, Zhonghua
    Jiang, Shibo
    Dai, Qiuyun
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2008, 105 (42) : 16332 - 16337
  • [33] Enfuvirtide (T20)-Based Lipopeptide Is a Potent HIV-1 Cell Fusion Inhibitor: Implications for Viral Entry and Inhibition
    Ding, Xiaohui
    Zhang, Xiujuan
    Chong, Huihui
    Zhu, Yuanmei
    Wei, Huamian
    Wu, Xiyuan
    He, Jinsheng
    Wang, Xinquan
    He, Yuxian
    JOURNAL OF VIROLOGY, 2017, 91 (18)
  • [34] Improved Pharmacological and Structural Properties of HIV Fusion Inhibitor AP3 over Enfuvirtide: Highlighting Advantages of Artificial Peptide Strategy
    Zhu, Xiaojie
    Zhu, Yun
    Ye, Sheng
    Wang, Qian
    Xu, Wei
    Su, Shan
    Sun, Zhiwu
    Yu, Fei
    Liu, Qi
    Wang, Chao
    Zhang, Tianhong
    Zhang, Zhenqing
    Zhang, Xiaoyan
    Xu, Jianqing
    Du, Lanying
    Liu, Keliang
    Lu, Lu
    Zhang, Rongguang
    Jiang, Shibo
    SCIENTIFIC REPORTS, 2015, 5
  • [35] Improved Pharmacological and Structural Properties of HIV Fusion Inhibitor AP3 over Enfuvirtide: Highlighting Advantages of Artificial Peptide Strategy
    Xiaojie Zhu
    Yun Zhu
    Sheng Ye
    Qian Wang
    Wei Xu
    Shan Su
    Zhiwu Sun
    Fei Yu
    Qi Liu
    Chao Wang
    Tianhong Zhang
    Zhenqing Zhang
    Xiaoyan Zhang
    Jianqing Xu
    Lanying Du
    Keliang Liu
    Lu Lu
    Rongguang Zhang
    Shibo Jiang
    Scientific Reports, 5
  • [36] Enfuvirtide approved for defusing HIV
    Burton, A
    LANCET INFECTIOUS DISEASES, 2003, 3 (05): : 260 - 260
  • [37] Enfuvirtide (Fuzeon) for HIV infection
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2003, 45 (1159): : 49 - 50
  • [38] Evaluating membranotropism of HIV-1 fusion inhibitor peptides enfuvirtide and T-1249 in blood cells. Implications for mode of action
    Matos, P. M.
    Castanho, M. A. R. B.
    Santos, N. C.
    FEBS JOURNAL, 2010, 277 : 291 - 291
  • [39] Adherence to enfuvirtide and its impact on treatment efficacy
    Rockstroh, Juergen
    Dejesus, Edwin
    Donatacci, Lucille
    Wat, Cynthia
    Bertasso, Anne
    Labriola-Tompkins, Emily
    Shikhman, Anna
    Atkins, Belinda
    Guimaraes, Denise
    Wilkinson, Martin
    Thommes, James
    Rowell, Lucy
    Demasi, Ralph
    Salgo, Miklos
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2008, 24 (02) : 141 - 148
  • [40] Enfuvirtide (T-20): A novel human immunodeficiency virus type 1 fusion inhibitor
    Cervia, JS
    Smith, MA
    CLINICAL INFECTIOUS DISEASES, 2003, 37 (08) : 1102 - 1106